MedTrace Logo

Can we Improve Mortality Prediction in Patients With Sepsis in the Emergency Department

NCT06338111 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2024-06-07

No results posted yet for this study

Summary

This study aims to identify the prognostic role of procalcitonin (PCT), soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1), the soluble form of the urokinase plasminogen activator receptor (suPAR), highly sensitive C-reactive protein (hs-CRP), Interleukin-6 (IL-6), and azurocidin 1 (AZU1) in 28-day mortality for patients with sepsis in Emergency Department.

Conditions

  • Sepsis Syndrome
  • Emergency Department
  • Biomarker

Interventions

DIAGNOSTIC_TEST

ELISA Sepsis Biomarkers dosage

Observational

Sponsors & Collaborators

  • Iuliu Hatieganu University of Medicine and Pharmacy

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-09
Primary Completion
2022-12-06
Completion
2023-04-30

Countries

  • Romania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06338111 on ClinicalTrials.gov